Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

2014 Archives

Dec 18, 2014

Philadelphia, PA – December 18, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its...

More
Dec 5, 2014
Talented Leader Brings Senior Level Operations, Global Experience

Philadelphia, PA – December 5, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Michael J. Bogda as president, effective December 1, 2014. Arthur Bedrosian...

More
Dec 2, 2014

Philadelphia, PA – December 2, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday,...

More
Nov 17, 2014
Ernest Sabo, Vice President of Regulatory Affairs and Chief Compliance Officer, To Retire After a Distinguished 45-year Career, 10 years at Lannett

Philadelphia, PA – November 17, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that Ernest J. Sabo, the company’s vice president of regulatory affairs and chief compliance...

More
Nov 3, 2014

Philadelphia, PA – November 3, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has completed its cGMP compliance inspection of...

More
Nov 3, 2014
Company Raises Outlook for Fiscal 2015

Philadelphia, PA – November 3, 2014 – Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 first quarter ended September 30, 2014.\ For the fiscal...

More
Oct 29, 2014

Philadelphia, PA – October 29, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Credit-Suisse 2014 Healthcare Conference on Tuesday,...

More
Oct 29, 2014

Philadelphia, PA – October 29, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its...

More
Oct 23, 2014
Company to Report Full Financial Results, Host Conference Call on November 3

Philadelphia, PA – October 23, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2015 first quarter net sales of approximately $93 million and...

More
Sep 30, 2014

Philadelphia, PA – September 30, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the class action lawsuit filed against the company and certain officers in the United...

More
Sep 22, 2014
Strong Sales of Digoxin Continue; Company Reaffirms Fiscal 2015 Guidance

Philadelphia, PA – September 22, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution...

More
Sep 16, 2014
Company Concludes It Is in Compliance with Applicable Laws and Regulations

Philadelphia, PA – September 16, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that upon receipt of the subpoena from the State of Connecticut Office of the Attorney General...

More
Sep 10, 2014

Philadelphia, PA – September 10, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its...

More
Aug 28, 2014

Philadelphia, PA – August 28, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Morgan Stanley Global Healthcare Conference 2014 on Monday,...

More
Aug 27, 2014
Company Reports Seventh Consecutive Quarter of Record Net Sales Totaling $81 Million, Gross Margin of 69%, EPS of $0.64; Guides to Strong Fiscal 2015

Philadelphia, PA – August 27, 2014 – Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2014 fourth quarter and full year ended June 30, 2014. For the...

More
Aug 20, 2014

Philadelphia, PA – August 20, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and...

More
Aug 20, 2014

Philadelphia, PA – August 20, 2014 – Lannett Company, Inc. (NYSE: LCI) today commented on the utilization of Digoxin, following a recently published abstract in the Journal of the...

More
Aug 18, 2014
Company Expects To Report Full Financial Results, Host Conference Call On Wednesday, August 27th

Preliminary Fiscal 2014 Financial Results: Fourth quarter: Net sales of $81 million; EPS between $0.60 and $0.64 Full year: Net sales of $274 million; Adjusted EPS between $1.94 and $1.98...

More
Aug 5, 2014

Philadelphia, PA – August 5, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday,...

More
Aug 4, 2014

Philadelphia, PA – August 4, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated...

More
Jul 17, 2014

Philadelphia, PA – July 17, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has signed an agreement with Symplmed, Inc. to be the exclusive distributor in the United...

More
Jul 16, 2014

Philadelphia, PA – July 16, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received interrogatories and subpoena from the State of Connecticut Office of the...

More
Jun 16, 2014

Philadelphia, PA – June 16, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated...

More
Jun 2, 2014

Philadelphia, PA – June 2, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will be added to the S&P SmallCap 600 Index today, after the close of trading....

More
May 12, 2014

Philadelphia, PA – May 12, 2014 – Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into distribution and contract manufacturing services agreements with Sunshine...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products